Pluristem Therapeutics
-
Biologics
$8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program
HAIFA, Israel, Sept. 05, 2017 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy…
Read More » -
Biologics
Pluristem & Charite Expand Cooperation Agreement to Include Orthopedic Indications
HAIFA, Israel, Oct. 12, 2015 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products,…
Read More »